Former Aetna CEO Ron Williams weighs in on what changes could be ahead for the Affordable Care Act and consumers. » Read More
By: Dan Mangan
UnitedHealth denies allegations it gamed the nation's Medicare system for hundreds of millions of dollars. » Read More
By: Elizabeth Gurdus
The burdens of repealing and replacing Obamacare will fall on consumers, Mark Cuban tells CNBC. » Read More
By: Bertha Coombs
House Speaker Paul Ryan said they plan to introduce legislation as early as next Tuesday. » Read More
Mylan CEO Heather Bresch is set to testify Wednesday before a House committee over sky-high price hikes for lifesaving EpiPens.
Less than 10 percent of authorized doctors prescribe the medication buprenorphine to more than 75 patients.
Shares of Sarepta Therapeutics jumped more than 13 percent in Tuesday trade after closing higher Monday on government approval of its drug.
GlaxoSmithKline said it had chosen its head of consumer health care, Emma Walmsley, as its new CEO, after considering other candidates.
Despite rising Obamacare prices, the total premiums paid in many cases are less than work-based coverage.
Shares of Sarepta Therapeutics briefly surge after the FDA approved its muscular dystrophy drug eteplirsen.
RSV — or respiratory syncytial virus — has been a problem that's thwarted medicine for more than half a century.
Workers are being forced to pay more out of pocket for health care than in the past.
People in consumer-directed health plans tend to pay much more out of pocket for health care than others despite lower use.
Employers may be leery about shifting more health costs to their employees, according to the results from two health benefits surveys.
Republicans want to repeal Obamacare, but millions of people could lose coverage if that happens.
The president dropped by a meeting with insurers Monday, and wrote all insurance companies selling Obamacare plans.
GAO investigators repeatedly managed to enroll fictitious applications in health coverage.
Just 8.6 percent of people lack health insurance now, according to a survey.
Year-to-date EpiPen prescriptions increased over last year even as prices rose.
New crackdowns on special enrollments have already led to a drop in such Obamacare sign-ups.
Two U.S. senators have also asked the Federal Trade Commission to look into Mylan's EpiPen sales to schools.
Gilead Sciences rose Tuesday after it was upgraded, citing confidence in the prospects for Gilead's HIV treatments among other factors.
German drugmaker Bayer and Monsanto are closing in on a deal, with Monsanto telling Bayer that it is "close" on price, sources told CNBC Tuesday.
Hillary Clinton released a plan to combat drug price hikes, following the latest outcry over Mylan's nearly 400 percent price increase for EpiPens.
Get the best of CNBC in your inbox